Analyst Reports Pernix Therapeutics Holdings, Inc. is Laying the Foundation for a Turnaround

ACCESSWIRE - Posted 3 years ago

NEW YORK, NY / ACCESSWIRE / February 14, 2019 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Pernix Therapeutics Holdings, Inc., (PTX) Pernix is the parent company of Pernix Therapeutics, LLC, a specialty pharmaceutical business focused on acquiring and commercializing prescription drugs, primarily for the U.S. market.

From a business perspective, Pernix team is working very closely with Nalpropion to support their commercial and marketing efforts. During the third quarter, Contrave remained the leading prescription weight loss brand in the United States, and the company is currently exploring a number of initiatives to enhance the value of the brand globally.

This full report explores the initiatives for a turnaround, revenue and progress READMORE

Copy and paste to your browser may be required to view the report -

In the last quarter, the company' primary asset - Zohydro ER generated its third consecutive quarter of year-over-year net revenue growth in the third quarter. Besides, the management views Contrave as a critical element of its strategic plan. Pernix is extremely encouraged with the initial results from Contrave, which is the market-leading branded weight loss prescription drug. Contrave sales were $16.4 million in the third quarter, which included only two months of sales from this product.

The full research report available with no obligation covers currently approved products, respective revenues and more READ MORE

Copy and paste to your browser may be required to view the report -

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TNS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

CONTACT: [email protected]

SOURCE: Traders News Source

View source version on